PRF Technologies Ltd. (PRFX): R&D Expense
$1.14M
Year ended 2025-12-31
-36.4%
3-year compound annual growth
+26.3%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.14M | -90.3% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $11.71M | +94.0% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $6.04M | +36.5% | 2026-03-26, From 2023-01-01 |
| 2022-12-31 | $4.42M | +54.6% | 2025-04-07, From 2022-01-01 |
| 2021-12-31 | $2.86M | +707.9% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $354.0K | +160.3% | 2023-03-15, From 2020-01-01 |
| 2019-12-31 | $136.0K | -39.0% | 2022-03-16, From 2019-01-01 |
| 2018-12-31 | $223.0K | n/a | 2021-03-18, From 2018-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $1.14M | -90.3% |
| Jupiter Neurosciences, Inc. (JUNS) | 2025-12-31 | $2.09M | +323.5% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $6.03M | -10.2% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $340.0K | +22.3% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $158.68M | -7.5% |
| Genelux Corp (GNLX) | 2025-12-31 | $19.85M | +4.5% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $3.64M | +19.5% |
| Altimmune, Inc. (ALT) | 2025-12-31 | $66.43M | -19.2% |
| Aspire Biopharma Holdings, Inc. (ASBP) | 2025-12-31 | $923.9K | +540.0% |
Compare PRFX, JUNS, TLPH, IBO side by side · Screen every company in Pharmaceutical Preparations ↗